TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Test the Effects of Riociguat in Patients With Pulmonary Hypertension Associated With Left Ventricular Diastolic Dysfunction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female patients with symptomatic pulmonary hypertension due to left ventricular diastolic dysfunction~Exclusion Criteria:~* Types of pulmonary hypertension other than group 2.2 of Dana Point Classification

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Type: EXPERIMENTAL): None
- Arm 2 (Type: EXPERIMENTAL): None
- Arm 3 (Type: EXPERIMENTAL): None
- Arm 4 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Fibroid Ablation Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* 28 years of age or older~* Regular, consistent menstrual cycles~* History of excessive bleeding~* One Menstrual Pictogram score ≥ 120 during a one-month screening period~* Baseline Uterine Fibroid Symptom \& Quality of Life (UFS-QOL) Symptom Severity Subscale (SSS) score ≥ 20~* Between 1 and 5 Target Fibroids between 1 cm and 5 cm and/or maximum volume 82.4cc~* At least one fibroid must indent the endometrium~* Subject is not at material risk for pregnancy.~* Subject is willing to maintain use or non-use of hormonal contraception~* Subject is willing to have uniform maintenance (use or non-use) of any antifibrinolytic or nonsteroidal anti-inflammatory agents~Exclusion Criteria:~* Subserosal fibroids with bulk symptoms~* Presence of type 0 intracavitary fibroids~* Any Target Fibroid \> 5 cm in maximum diameter with a volume \> 82.4cc~* Any fibroid that obstructs access of the VizAblate probe~* Postmenopausal by history~* Desire for current or future fertility~* Hemoglobin \< 6 g/dl~* Pregnancy~* Evidence of disorders of hemostasis~* Use of Gonadotropin-releasing hormone (GnRH) agonist or implantable or injectable progestin and/or estrogen, Selective Estrogen Receptor Modulators (SERM) or selective progesterone receptor modulator (SPRM)~* Short-term use of hormonal medication for management of bleeding~* Evidence for current cervical dysplasia~* Endometrial hyperplasia~* Confirmed abdominal / pelvic malignancy within the previous five years~* Active pelvic infection~* Clinically significant adenomyosis~* Previous uterine artery embolization. Previous surgical or ablative treatment for fibroids or menorrhagia within previous 12 months~* Current use of anticoagulant therapy~* Need for emergency surgery to treat fibroid symptoms~* Concomitant intrauterine polyps \> 1.0 cm~* Contraindication to MRI~* Renal insufficiency~* Uncontrolled hypertension lasting 2 years or more~* One or more treatable fibroids that are calcified~* Chronic pelvic pain~* Presence of an extrauterine pelvic mass~* Presence of a tubal implant for sterilization~* Previous pelvic irradiation~* Endometrial cavity length \< 4.5 cm

- Gender: FEMALE
- Minimum Age: 28 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- VizAblate treatment (Type: EXPERIMENTAL): VizAblate System: subject acts as her own control

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Comparing Two Palliative Schemes of Radiotherapy for Head and Neck Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~• Newly diagnosed patients with primary non-metastatic carcinoma located in the oral cavity, oropharynx, larynx (except T1 glottic), hypopharynx, nasopharynx, paranasal sinuses and salivary gland and carcinoma of unknown primary in the head and neck region who are not suitable for radical treatment with surgery or (chemo) and, therefore, planned for treatment with radiotherapy in palliative setting.~OR~* Newly diagnosed patients with primary head and neck carcinoma with limited metastatic disease in a good general condition and few comorbidities (ACE-25 \<3) with life expectancy of at least 6 months are also eligible.~* No chemotherapy or surgery is allowed before inclusion.~* Age ≥ 18 years~* WHO performance status 0-2~* Signed written informed consent~Exclusion Criteria:~* Patients with previously radiation treatment in the head and neck region, for any reason.~  \* Chemotherapy or surgery for head and neck tumor before inclusion and no other concomitant anti-cancer therapy is allowed during study treatment.~* Patients with head and neck malignancies arising from skin, nose, thyroid gland or esophagus.~* Patients with advanced stage sarcoma or lymphoma of the head and neck region.~* Expected life expectancy of less than 3 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- arm 1: 6 fractions of radiation (Type: ACTIVE_COMPARATOR): radiation in a 6 fractions scheme and a daily dose of 6 Gy
- arm 2: 16 fractrions of radiation (Type: ACTIVE_COMPARATOR): radiation in a 16 fractions scheme and a daily dose of 3.125 Gy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Two-Part, Open-Label, Multi-Center, Phase 1/2 Study of BIW-8962 as Monotherapy in Subjects With Lung Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Phase 1: histopathological-documented, measurable or non-measurable unresectable, advanced primary or recurrent SCLC, NSCLC or mesothelioma~* Phase 2: measurable, unresectable advanced or recurrent SCLC~* A life expectancy \> 3 months~* Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1 at study entry~* Echocardiogram or multigated acquisition (MUGA) scan with left ventricular ejection fraction (LVEF) ≥ 50%, or ≥ institution's established lower limit of normal~* Adequate hematologic, hepatic, renal and lung function~Exclusion Criteria:~* Subject received cytotoxic anti-cancer chemotherapy, orally available signaling pathway-targeted therapy, hormonal therapy, radiotherapy, immunotherapy, or investigational agents within 3 weeks prior to the first dose~* Subject received monoclonal antibodies within 4 weeks of the first dose~* Major surgery within 4 weeks prior to the first dose~* Known symptomatic brain metastases~* Clinically significant cardiovascular disease~* Leptomeningeal disease~* Uncontrolled intercurrent illness including ongoing or active infection, uncontrolled diabetes, etc~* Known HIV disease or acquired immunodeficiency syndrome-related illness~* A psychiatric illness, disability or social situation~* Hypersensitivity reaction to monoclonal antibodies, other therapeutic proteins~* A history of primary brain/CNS malignancy~* Neurological paraneoplastic syndrome

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- BIW-8962 (Type: EXPERIMENTAL): Phase 1 - Dose escalation based on the BIW-8962 tolerability and safety data obtained from three subjects enrolled in a cohort (first cycle of treatment), enrollment at the next dose level or additional subjects into the ongoing cohort will occur~Phase 2 - Recommended dose determined in Phase 1

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Study of Evobrutinib in Participants With Relapsing Multiple Sclerosis (RMS)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria: - Participants are diagnosed with RMS (relapsing-remitting multiple sclerosis \[RRMS\] or secondary progressive multiple sclerosis \[SPMS\] with relapses) in accordance with 2017 Revised McDonald criteria (Thompson 2018) - Participants with one or more documented relapses within the 2 years before Screening with either: a. one relapse which occurred within the last year prior to randomization, OR b. the presence of at least 1 gadolinium-enhancing (Gd+) T1 lesion within 6 months prior to randomization - Participants have Expanded Disability Status Scale (EDSS) score of 0 to 5.5 at Baseline. Participants with an EDSS score \<= 2 at Screening are only eligible for participation if their disease duration (time since onset of symptoms) is no more than 10 years - Participants are neurologically stable for \>= 30 days prior to both screening and baseline - Female participants must be neither pregnant nor breast-feeding and must lack child-bearing potential, as defined by either: post-menopausal or surgically sterile or use an effective method of contraception for the duration of the study - Participants have given written informed consent prior to any study-related procedure - Other protocol defined inclusion criteria could apply Exclusion Criteria: - Participants diagnosed with Progressive MS, in accordance with the 2017 Revised McDonald criteria as follows: a). Participants with Primary Progressive MS. b). Participants with secondary progressive MS without evidence of relapse.~* Disease duration more than (\>) 10 years in participants with an EDSS =\< 2.0 at screening.~* Immunologic disorder other than MS, or any other condition requiring oral, intravenous (IV) , intramuscular, or intra-articular corticosteroid therapy, with the exception of well-controlled Type 2 diabetes mellitus or well controlled thyroid disease.~* Other protocol defined exclusion criteria could apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Evobrutinib + Avonex® matched Placebo (Type: EXPERIMENTAL): Participants received active evobrutinib twice daily (BID) along with concomitant intramuscular (IM) injection of placebo matched to Avonex® once a week. Treatment period was planned to be of 96 weeks.
- Avonex® + Evobrutinib matched Placebo (Type: ACTIVE_COMPARATOR): Participants received IM injection of active Avonex® once a week along with concomitant placebo matched to evobrutinib BID. Treatment period was planned to be of 96 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Phase II Trial of Neoadjuvant Metronomic Chemotherapy in Triple-Negative Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Women with Estrogen Receptor (ER), Progesterone Receptor (PR),and HER2 negative invasive breast cancer confirmed on core biopsy.(Note: HER2 negative by FISH preferred; HER2 0 or 1+ by IHC acceptable)~* Primary tumor size 2cm or greater by physical exam or radiographic measurements.(Note: Locally advanced T4 or inflammatory breast cancer is eligible.)~* Assessment of pre-treatment axillary lymph nodal status (Note: FNA biopsy if palpable or sentinel lymph node biopsy (SLNB) if not palpable preferred; clinical exam acceptable.)~* Absolute neutrophil count \> 1500 mm3 and platelet count \> 100,000 mm3~* Normal myocardial left ventricular function~* Serum creatinine \< 2.0 mg/dl~* Total bilirubin and AST \< 3X upper limits normal~Exclusion Criteria:~* Recurrent or metastatic breast cancer findings (Note: If oncologically felt to be a second breast primary, patient eligible for this protocol)~* Another active cancer present~* Medical contraindications to chemotherapy or surgery~* First trimester pregnancy~* Breast feeding

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Neoadjuvant metronomic AC followed by weekly TC (Type: EXPERIMENTAL): Neoadjuvant chemotherapy with metronomic AC followed by weekly TC then surgery

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: STIP: Statin Trial for Influenza Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients with suspected or confirmed influenza (Appendix A)~2. Requirement for ICU (or ICU step-down) admission due to respiratory distress defined as:~   * SaO2/FiO2 \< 315 or PaO2/FiO2 \< 300~  * Multiply by PB/760 (when altitude exceeds 51000 ft)~  * For FiO2 for non-intubated patients see Appendix B~Participants must receive the first dose of study drug within 48 hours following ICU admission for confirmed or suspected influenza or be excluded from participation in the study.~Exclusion Criteria:~1. No consent/inability to obtain consent~2. Age less than 13 years~3. Weight less than 40 kg~4. Unable to receive or unlikely to absorb enteral study drug (e.g. patients with partial or complete mechanical bowel obstruction, intestinal ischemia, infarction, and short bowel syndrome)~5. Allergy or intolerance to statins\*~6. Pregnancy or breast feeding~7. Receiving niacin, fenofibrate, cyclosporine, gemfibrozil, or any antiviral protease inhibitor including but not limited to lopinavir and ritonavir.~8. Existing clinically significant myositis or myopathy or has a measured CK greater than 5,000 U/L~9. Requiring statin for underlying disease as determined by the patients attending physician team\*\*.~10. Severe chronic liver disease (Child-Pugh Score 11-15)~11. Previous myocardial infarction or thrombotic stroke within the past 6 months 11.12. Any significant funding in the patient's medical history or physical or psychiatric exam prior to randomization that, in the opinion of the investigator, would affect patient safety or compliance or ability to deliver the study drug according to protocol

- Gender: ALL
- Minimum Age: 13 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo tablet (Type: PLACEBO_COMPARATOR): Placebo
- Rosuvastatin (crestor) (Type: EXPERIMENTAL): Experimental arm

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Mifepristone Induction for Fetal Demise

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Intrauterine fetal death as confirmed by absence of cardiac motion on ultrasound by Attending physician at the time of admission to the hospital.~2. Estimated gestational age greater than 20 weeks~3. Hemodynamically stable and appropriate for induction of labor as per primary clinical health team in house~4. Women with one prior low transverse cesarean delivery~Exclusion Criteria:~1. History of 2 or more low transverse cesarean deliveries~2. Prior classical cesarean delivery~3. History of abdominal myomectomy~4. Known or suspected allergic reaction to mifepristone~5. Known or suspected adrenal gland disease~6. Known or suspected bleeding diatheses or coagulopathies~7. Known or suspected use of QTc-prolonging medication~8. Known maternal medical or physical conditions that prohibits vaginal delivery

- Gender: FEMALE
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- mifepristone (Type: ACTIVE_COMPARATOR): following informed consent women will be randomized and the mifepristone group will take 200 mg by mouth immediately prior to induction of labor for fetal demise on labor and delivery
- placebo pill (Type: PLACEBO_COMPARATOR): following informed consent women will be randomized and the placebo group will take a placebo pill by mouth (similar in properties to the mifepristone group, but it will lack any active drug) immediately prior to induction of labor for fetal demise on labor and delivery

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Asthma/Steroid Withdrawal Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Non-smoker (less than 1 pack-year).~2. Age greater than 18 years old.~3. Ability to obtain informed consent.~4. Pulmonary Function Tests demonstrating greater than 12% FEV1 reversibility following beta agonist OR a methacholine challenge consistent with airways hyper-reactivity.~5. Evidence of atopy on standardized skin test battery.~6. Mild to moderate persistent asthma classification by GINA guidelines.~7. No severe exacerbations in the preceding 3 months (defined as emergency room visit, course of oral prednisone or hospitalization).~8. Access to internet.~Exclusion Criteria:~1. Unstable asthma.~2. Patient not on inhaled corticosteroids.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Intermittent Versus Continuous Subglottic Secretion Drainage on Tracheal Mucosa Damages

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult aged 18 years or more~* Patients hospitalized in intensive care unit~* Patients requiring endotracheal tube with an expected mechanical ventilation duration of more than 24 hours~Exclusion Criteria:~* Pregnant or breast-feeding women~* Previous known tracheal lesions~* Persons deprived of freedom

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intermittent drainage (Type: EXPERIMENTAL): Intermittent subglottic secretion drainage at -100 mmHg during 8 sec every 15 seconds.
- Continuous drainage. (Type: ACTIVE_COMPARATOR): Continuous subglottic secretion drainage at -20 mmHg.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Current diagnosis of Chronic Kidney Disease, either receiving or not receiving dialysis~* Anemic, with two consecutive screening hemoglobin values drawn at least 7 days apart \< 11.0 g/dL~* Transferrin saturation (Tsat) greater than or equal to 20%~Exclusion Criteria:~* Any erythropoiesis stimulating agent (ESA) use within 12 weeks prior to randomization~* other hematologic disorders~* upper or lower gastrointenstinal bleeding within 6 months prior to randomization~* uncontrolled hypertension~* prior history (within 12 weeks prior to randomization) of acute myocardial ischemia, hospitalization for congestive heart failure, myocardial infarction, stroke or transient ischemic attack~* prior history (within 6 months prior to randomization) of thromboembolism

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Darbepoetin Alfa QW (Type: EXPERIMENTAL): Participants received darbepoetin alfa once a week (QW) for 24 weeks. The initial dose was 0.45 μg/kg; thereafter, active doses were administered to achieve and then maintain hemoglobin levels within a target range of 10.0 to 12.0 g/dL. Participants not on dialysis or who were receiving peritoneal dialysis were administered darbepoetin alfa subcutaneously; participants receiving hemodialysis were administered darbepoetin alfa intravenously.
- Darbepoetin Alfa Q2W (Type: EXPERIMENTAL): Participants received darbepoetin alfa every 2 weeks (Q2W) and a placebo every other 2 weeks to maintain the blind for 24 weeks. The initial dose was 0.75 μg/kg; thereafter, active doses were administered to achieve and then maintain hemoglobin levels within a target range of 10.0 to 12.0 g/dL. Participants not on dialysis or who were receiving peritoneal dialysis were administered darbepoetin alfa subcutaneously; participants receiving hemodialysis were administered darbepoetin alfa intravenously.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility